MET and non-small cell lung carcinoma: Furthermore, despite bearing EGFR-activating mutations, NSCLC patients with increased MET expression relative to EGFR (or decreased EGFR/MET ratio) experienced a worse clinical outcome with short median PFS (1.0 vs. 11.2 months, p = 0.0008 with EGFR/MET ratio cut-off of 2; 1.0 vs. 11.5 months, p = 0.0099 with EGFR/MET ratio cut-off of 3, Fig. 3).